Giuseppe Di Caro

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/12023706/publications.pdf

Version: 2024-02-01

623734 794594 2,098 18 14 19 citations g-index h-index papers 19 19 19 4618 docs citations times ranked citing authors all docs

#	Article	IF	CITATIONS
1	Immunosuppressive plasma cells impede T-cell-dependent immunogenic chemotherapy. Nature, 2015, 521, 94-98.	27.8	451
2	Interleukin-17 Receptor A Signaling in Transformed Enterocytes Promotes Early Colorectal Tumorigenesis. Immunity, 2014, 41, 1052-1063.	14.3	265
3	Occurrence of Tertiary Lymphoid Tissue Is Associated with T-Cell Infiltration and Predicts Better Prognosis in Early-Stage Colorectal Cancers. Clinical Cancer Research, 2014, 20, 2147-2158.	7.0	264
4	Dual prognostic significance of tumour-associated macrophages in human pancreatic adenocarcinoma treated or untreated with chemotherapy. Gut, 2016, 65, 1710-1720.	12.1	193
5	Fructose stimulated de novo lipogenesis is promoted by inflammation. Nature Metabolism, 2020, 2, 1034-1045.	11.9	174
6	Spatial distribution of B cells predicts prognosis in human pancreatic adenocarcinoma. Oncolmmunology, 2016, 5, e1085147.	4.6	169
7	Occurrence and significance of tumorâ€associated neutrophils in patients with colorectal cancer. International Journal of Cancer, 2016, 139, 446-456.	5.1	141
8	Stress-Activated NRF2-MDM2 Cascade Controls Neoplastic Progression in Pancreas. Cancer Cell, 2017, 32, 824-839.e8.	16.8	97
9	Tumor-associated macrophages and response to 5-fluorouracil adjuvant therapy in stage III colorectal cancer. Oncolmmunology, 2017, 6, e1342918.	4.6	90
10	YAP–IL-6ST autoregulatory loop activated on APC loss controls colonic tumorigenesis. Proceedings of the National Academy of Sciences of the United States of America, 2017, 114, 1643-1648.	7.1	85
11	Immune cells: plastic players along colorectal cancer progression. Journal of Cellular and Molecular Medicine, 2013, 17, 1088-1095.	3.6	62
12	Circulating Inflammatory Mediators as Potential Prognostic Markers of Human Colorectal Cancer. PLoS ONE, 2016, 11, e0148186.	2.5	30
13	Tertiary Lymphoid Tissue in the Tumor Microenvironment: From Its Occurrence to Immunotherapeutic Implications. International Reviews of Immunology, 2015, 34, 123-133.	3.3	26
14	MSH3 Protein Expression and Nodal Status in MLH1-Deficient Colorectal Cancers. Clinical Cancer Research, 2012, 18, 3142-3153.	7.0	21
15	Tertiary lymphoid tissue. Oncolmmunology, 2014, 3, e28850.	4.6	9
16	Mast cells are not associated with systemic insulin resistance. European Journal of Clinical Investigation, 2016, 46, 911-919.	3.4	8
17	Immune mediators as potential diagnostic tools for colorectal cancer: from experimental rationale to early clinical evidence. Expert Review of Molecular Diagnostics, 2014, 14, 387-399.	3.1	6
18	Immune-based therapies in pancreatic and colorectal cancers and biomarkers of responsiveness. Expert Review of Anticancer Therapy, 2014, 14, 1219-1228.	2.4	1